- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DEVONIAN HEALTH GROUP Aktie jetzt für 0€ handeln | |||||
| 11.09. | Devonian Health Group Inc (2): Devonian expects to begin trading on NYSE American | 1 | Stockwatch | ||
| 11.09. | Devonian Health strebt Notierung an der NYSE American für kommende Woche an | 2 | Investing.com Deutsch | ||
| 11.09. | Devonian Health plans NYSE American listing next week | 1 | Investing.com | ||
| 11.09. | Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American | 152 | PR Newswire | QUEBEC, Sept. 11, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection... ► Artikel lesen | |
| 02.09. | Devonian Health Group Inc. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 02.09. | Devonian Health Group Inc (2): Devonian completes QC validation for thykamine process | 2 | Stockwatch | ||
| 01.09. | Devonian Health Group Strengthens Thykamine Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay | 1 | CNW | ||
| 19.08. | Devonian Health Group Inc (2): Devonian Health to start trading on NYSE Aug. 21 | 1 | Stockwatch | ||
| 18.08. | Devonian Health Group Inc.: Devonian Health Group Anticipates to Commence Trading on the NYSE American | 194 | PR Newswire | QUEBEC, Aug. 18, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection... ► Artikel lesen | |
| 28.07. | Devonian Health Group Inc.: Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering | 194 | PR Newswire | QUÉBEC, July 27, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 27.07. | Devonian Health Group Inc. - F-1, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 22.07. | Devonian Health Group Inc (2): Devonian receives Health Canada OK for phase 2/3 study | 1 | Stockwatch | ||
| 21.07. | Devonian Health Group Inc.: Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years | 271 | PR Newswire | The primary objective of the study is to evaluate the efficacy of Thykamine compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily... ► Artikel lesen | |
| 30.06. | Devonian Health Group Inc.: Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 | 178 | PR Newswire | (all amounts are in Canadian dollars)
Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share
Nine months ended April 30, 2026, net... ► Artikel lesen | |
| 31.03. | Devonian Health Group Inc (2): Devonian Health shareholders approve AGM resolutions | 1 | Stockwatch | ||
| 30.03. | Devonian Health Group Inc.: Devonian Reports Results of its Annual General and Special Meeting of Shareholders | 270 | PR Newswire | QUÉBEC, March 30, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 26.03. | Devonian Health Group GAAP EPS of -$0.81 | 1 | Seeking Alpha | ||
| 26.03. | Devonian Health Group Inc (2): Devonian Health loses $2.2-million in Q2 | 4 | Stockwatch | ||
| 25.03. | Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026 | 619 | PR Newswire | (all amounts are in Canadian dollars)
Quarter ended January 31, 2026, net loss of $2.2 million dollars, ($0.81) per share
Six months ended January 31, 2026, net... ► Artikel lesen | |
| 12.02. | Devonian Health Group Inc.: Devonian reports additional molecular data from MASH liver study | 440 | PR Newswire | Gene expression analysis from the STAM mouse model attributes Thykamine with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver
... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 49,310 | -0,48 % | Bayer verkauft Krebsmedikament an Grünenthal für bis zu 375 Mio Euro | DJ Bayer verkauft Krebsmedikament an Grünenthal für bis zu 375 Mio Euro
Von Adria Calatayud
DOW JONES--Bayer verkauft die Rechte an seinem Krebsmedikament Stivarga an Grünenthal. Wie das Aachener... ► Artikel lesen | |
| MERCK KGAA | 132,95 | -0,15 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| JAGUAR HEALTH | 9,010 | +1,12 % | XFRA NEW INSTRUMENTS AVAILABLE ON 17.09.2026 | The following instruments on XETRA do have their first trading 17.09.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 17.09.2026
Aktien
1 CNE100007DY4 Shenzhen Woer Heat-Shrinkable... ► Artikel lesen | |
| NOVO NORDISK | 33,845 | -2,41 % | Novo Nordisk strebt mehrere neue Blockbuster-Medikamente an | DJ Novo Nordisk strebt mehrere neue Blockbuster-Medikamente an
Von Dominic Chopping
DOW JONES--Novo Nordisk beabsichtigt, in den nächsten Jahren mehrere neue Blockbuster-Medikamente auf den... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 16,505 | -0,09 % | Generate Biomedicines auf dem Bernstein Healthcare Forum: Daten statt Modelle | ||
| APNIMED | 22,500 | 0,00 % | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 55,62 | +0,02 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| LB PHARMACEUTICALS | 39,160 | -0,08 % | LB Pharmaceuticals auf TD Cowen Summit: Wirkstoffkandidat LB-102 zielt auf sicherere psychiatrische Behandlungen ab | ||
| SCHOTT PHARMA | 23,800 | -0,83 % | Aktien Frankfurt: Dax macht Verluste wett - Ölpreis und Anleiherenditen im Fokus | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt hat sich am Dienstagnachmittag von seinen Anfangsverlusten vollständig erholt. Eine leichte Entspannung bei den Ölpreisen und bei den Anleiherenditen... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 21,290 | 0,00 % | Seaport Therapeutics: Wirkstoff-Pipeline gewinnt an Dynamik | ||
| KARDIGAN | 14,510 | -0,07 % | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| GSK | 21,970 | -1,08 % | Novo Nordisk investiert weitere 1,4 Milliarden Dollar in Biotech: Weshalb Big Pharma immer früher nach dem nächsten Milliardenmarkt sucht | ||
| OMNIAB | 4,780 | -0,21 % | Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb | VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 --
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,700 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm (dibutepinephrine) Sublingual Film | Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable... ► Artikel lesen | |
| TRISALUS LIFE SCIENCES | 4,970 | -0,60 % | TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support |
Das Unternehmen DEVONIAN HEALTH GROUP INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVONIAN HEALTH GROUP INC finden Sie auf Wallstreet Online.